Scott Schmidt
Addiction Medicine · Lincoln, NENPI 1609889336
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 78 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 23.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $496 and has fallen 78.7% since, to $105 in 2023.
Across 78 payments — averaging $17.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$332
- Gilead$328
- Otsuka America Pharmaceutical, Inc.$176
- Alkermes, Inc.$149
- Eisai Inc.$76
- Indivior Inc.$67
- plus $264 from 14 others
What the payments were for
- Food & beverage$1,392100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 19 | $332 |
| Gilead | 18 | $328 |
| Otsuka America Pharmaceutical, Inc. | 9 | $176 |
| Alkermes, Inc. | 8 | $149 |
| Eisai Inc. | 4 | $76 |
| Indivior Inc. | 4 | $67 |
| Biodelivery Sciences International, Inc. | 2 | $30 |
| Neurocrine Biosciences, Inc. | 2 | $28 |
| Heron Therapeutics, Inc. | 1 | $23 |
| Dermira, Inc. | 1 | $21 |
| Johnson & Johnson | 1 | $20 |
| Corium, LLC | 1 | $19 |
| Orexo US, Inc. | 1 | $18 |
| Boehringer Ingelheim | 1 | $18 |
| Abbott | 1 | $16 |
| Lundbeck LLC | 1 | $15 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| Bausch Health US, LLC | 1 | $15 |
| Novo Nordisk | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
How this compares
Too few addiction medicine providers in Nebraskato place this figure against a meaningful peer group, so we don't.
Other addiction medicine in Lincoln
- Claudia MooreOmaha$135
- Abraham FarhatOmaha$116
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.